BLASUBCUTANEOUSVIAL
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
KINERET (anakinra) by Swedish Orphan Biovitrum is interleukin 1 receptor antagonists [moa]. Approved for rheumatoid arthritis, adult-onset still's disease. First approved in 2001.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KINERET (anakinra) is a recombinant interleukin-1 receptor antagonist administered by subcutaneous injection, approved by the FDA on November 14, 2001. It is indicated for two rare genetic inflammatory conditions: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Anakinra blocks IL-1 signaling to reduce systemic inflammation in patients with these severe autoinflammatory disorders. As an orphan drug, it serves a specialized niche population with limited treatment alternatives.
$0.0BPart D
Mechanism of Action
Interleukin 1 Receptor Antagonists
Pharmacologic Class:
Interleukin-1 Receptor Antagonist
Indications (2)
Worked on KINERET at Swedish Orphan Biovitrum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.